Past 10 year's financial track record analysis by Moneyworks4me indicates that Infinium Pharmachem Ltd is a good quality company.
The key valuation ratios of Infinium Pharmachem Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Infinium Pharmachem Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|
| ROCE % ⓘ | 19.9% | 31.8% | 34.4% | 36.8% | 29.3% | - |
| Value Creation Index ⓘ | 0.4 | 1.3 | 1.5 | 1.6 | 1.1 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | ||||||
| Sales ⓘ | 36 | 54.6 | 74 | 101 | 122 | 122 |
| Sales YoY Gr. | - | 51.4% | 35.7% | 36.8% | 20.8% | - |
| Adj EPS ⓘ | 1 | 2.4 | 5.3 | 8.3 | 7.6 | 8 |
| YoY Gr. | - | 154.7% | 117.8% | 57.7% | -8.2% | - |
| BVPS (₹) ⓘ | 4.3 | 6.9 | 12.3 | 21.3 | 41.5 | 41.5 |
| Adj Net Profit ⓘ | 1 | 2.5 | 5.4 | 8.5 | 10.6 | 11 |
| Cash Flow from Ops. ⓘ | 2.3 | 6.8 | 9.1 | 7.4 | -15 | - |
| Debt/CF from Ops. ⓘ | 3.8 | 1.5 | 2.5 | 3.6 | -0.5 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | NA | 30.9% | 20.8% | ||||
| Adj EPS ⓘ | NA | NA | 46.6% | -8.2% | ||||
| BVPSⓘ | NA | NA | 81.6% | 94.5% | ||||
| Share Price | - | - | - | 27.8% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 22.4 | 43.4 | 54.7 | 49.4 | 26.7 | 19.2 |
| Op. Profit Mgn % ⓘ | 7.3 | 9 | 11.8 | 15 | 14.2 | NAN |
| Net Profit Mgn % ⓘ | 2.7 | 4.5 | 7.2 | 8.3 | 8.7 | 9.1 |
| Debt to Equity ⓘ | 2.1 | 1.5 | 1.8 | 1.2 | 0.1 | - |
| Working Cap Days ⓘ | 0 | 124 | 138 | 137 | 140 | 0 |
| Cash Conv. Cycle ⓘ | 0 | 50 | 54 | 68 | 91 | 0 |
Sales growth is growing at healthy rate in last 3 years 30.89%
Net Profit is growing at healthy rate in last 3 years 46.63%
Debt to equity has declined versus last 3 years average to 0.14
Return on Equity has declined versus last 3 years average to 19.20%
Sales growth is not so good in last 4 quarters at 0.00%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 8 | 8.1 |
| TTM Sales (₹ Cr.) | 122 | 136 |
| BVPS (₹.) ⓘ | 41.5 | 42.2 |
| Reserves (₹ Cr.) ⓘ | 44 | 45 |
| P/BV ⓘ | 7.44 | 7.31 |
| PE ⓘ | 38.71 | 38.00 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 0.00 / 0.00 |
| All Time Low / High (₹) | - / - |
| Market Cap (₹ Cr.) | 429 |
| Equity (₹ Cr.) | 13.9 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 57.2 |
| Pledged * | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|
| Sales | 36 | 55 | 74 | 101 | 122 |
| Operating Expenses ⓘ | 33 | 50 | 65 | 86 | 105 |
| Manufacturing Costs | 1 | 2 | 3 | 3 | 3 |
| Material Costs | 27 | 39 | 54 | 71 | 94 |
| Employee Cost | 2 | 2 | 2 | 2 | 3 |
| Other Costs ⓘ | 3 | 6 | 7 | 11 | 6 |
| Operating Profit ⓘ | 3 | 5 | 9 | 15 | 17 |
| Operating Profit Margin (%) | 7.3% | 9.0% | 11.8% | 15.0% | 14.2% |
| Other Income ⓘ | 1 | 1 | 1 | 1 | 2 |
| Interest ⓘ | 1 | 1 | 2 | 3 | 2 |
| Depreciation ⓘ | 1 | 1 | 1 | 1 | 2 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 1 | 4 | 7 | 12 | 15 |
| Tax ⓘ | 0 | 1 | 2 | 3 | 4 |
| Profit After Tax | 1 | 3 | 6 | 9 | 11 |
| PAT Margin (%) | 2.8% | 5.0% | 7.4% | 9.0% | 9.1% |
| Adjusted EPS (₹) | 1.0 | 2.7 | 5.4 | 9.0 | 8.0 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 4 | 7 | 13 | 22 | 58 | |||||
| Share Capital ⓘ | 1 | 1 | 1 | 5 | 14 | |||||
| Reserves ⓘ | 3 | 6 | 12 | 17 | 44 | |||||
| Minority Interest | 0 | 0 | 0 | 0 | 0 | |||||
| Debt | 9 | 11 | 22 | 26 | 8 | |||||
| Long Term Debt | 6 | 6 | 14 | 8 | 5 | |||||
| Short Term Debt | 3 | 5 | 9 | 18 | 3 | |||||
| Trade Payables | 6 | 11 | 10 | 9 | 8 | |||||
| Others Liabilities ⓘ | 1 | 2 | 4 | 4 | 5 | |||||
| Total Liabilities ⓘ | 21 | 31 | 49 | 60 | 78 | |||||
Fixed Assets | ||||||||||
| Gross Block | 7 | 8 | 8 | 21 | 24 | |||||
| Accumulated Depreciation | 3 | 3 | 4 | 5 | 8 | |||||
| Net Fixed Assetsⓘ | 4 | 4 | 4 | 16 | 16 | |||||
| CWIP ⓘ | 0 | 4 | 8 | 0 | 0 | |||||
| Investmentsⓘ | 0 | 0 | 0 | 0 | 0 | |||||
| Inventories | 7 | 9 | 14 | 18 | 22 | |||||
| Trade Receivables | 7 | 10 | 13 | 15 | 24 | |||||
| Cash Equivalents | 0 | 1 | 2 | 3 | 8 | |||||
| Others Assetsⓘ | 2 | 2 | 8 | 8 | 6 | |||||
| Total Assets ⓘ | 21 | 31 | 49 | 60 | 78 | |||||
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 2 | 7 | 9 | 7 | -15 |
| PBT ⓘ | 1 | 4 | 7 | 12 | 15 |
| Adjustment ⓘ | 2 | 2 | 2 | 4 | 4 |
| Changes in Working Capital ⓘ | -0 | 2 | 1 | -6 | -30 |
| Tax Paid ⓘ | 0 | -1 | -2 | -3 | -4 |
| Cash Flow From Investing Activity ⓘ | -1 | -5 | -7 | -3 | -3 |
| Capex | -1 | -5 | -5 | -5 | -3 |
| Net Investments | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 0 | 0 | -2 | 2 | 0 |
| Cash Flow From Financing Activityⓘ | -1 | -1 | -2 | -3 | 23 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 | 25 |
| Net Proceeds from Borrowing ⓘ | 0 | 0 | 0 | 0 | 0 |
| Interest Paid ⓘ | -1 | -1 | -2 | -3 | -2 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 0 | 0 | 0 | 0 | 0 |
| Net Cash Flow ⓘ | 0 | 1 | 0 | 2 | 5 |
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 23.59 | 47.87 | 56.17 | 53.43 | 27.92 | |||||
| ROCE (%) | 19.87 | 31.77 | 34.44 | 36.83 | 29.32 | |||||
| Asset Turnover Ratio | 1.75 | 2.13 | 1.86 | 1.85 | 1.77 | |||||
| PAT to CFO Conversion(x) | 2 | 2.33 | 1.5 | 0.78 | -1.36 | Working Capital Days | ||||
| Receivable Days | 75 | 60 | 58 | 51 | 58 | |||||
| Inventory Days | 68 | 51 | 56 | 58 | 60 | |||||
| Payable Days | 80 | 80 | 73 | 49 | 32 | |||||
The company was originally incorporated as ‘Infinium Pharmachem Private Limited’ on November 21, 2003 under the provisions of the Companies Act, 1956 vide Certificate of Incorporation issued by the Registrar of Companies, Ahmedabad, Gujarat. Later on, the company was converted into public limited company, the name of the company was changed to ‘Infinium Pharmachem Limited’ and fresh Certificate of Incorporation dated August 12, 2022 was issued by the Registrar of Companies, Ahmedabad, Gujarat.
The company was incorporated with the objective of manufacturing and supplying of various pharma related chemicals, bulk drugs, pharma intermediates etc. Accordingly, the company is dealing specifically and mainly in manufacturing and supplying of Iodine Derivatives, Pharma Intermediates and Active Pharmaceutical Ingredients (APIs). The company was formed with a vision to be globally integrated and admired Pharmaceutical & Healthcare Company.
The company undertakes Contract Research and Manufacturing Services (CRAMS) to provide customized and fully confidential solutions to its clients. Currently, the company’s manufacturing capabilities and technical expertise have efficiently catered numerous industries such as Pharmaceutical & Biotech, Specialty & Performance Chemicals, Agrochemicals, Human Health, Animal Health, Cosmetics, Sanitation, Electrical, Electronics and much more. The company has auditable manufacturing facility and it has been audited by various well known pharma giants worldwide. The Company currently provides the widest range of Iodine derivatives in the market, with more than 250 intermediates and over 15 APIs. All its products are developed to meet challenging demands, superior quality, performance and various other commercial requirements across industries.
The company has developed and maintained long - term healthy relationships with all its clients, including Pharmaceutical, Biotech and Fine Chemical companies and its products reach out to over 250+ clients globally. The company formed a Subsidiary Company in the name of Infinium Green Energy Private Limited on June 06th, 2022, The Company also formed a foreign Subsidiary as a Joint Venture (JV) with Shanghai Witofly Chemical Co. Ltd., in the name of Shanghai Tajilin Industrial Co. Ltd., in the People's Republic of China in the year 2019.
Business area of the company
The company is well focused to Iodine chemistry & this is the only core area of it. It is working as CRAMS, but its domain is very restricted to Iodine chemistry & it revolves around Iodine derivatives or Iodination. It manufactures & supply wide range of superior quality Iodine Derivatives & API Since 2003. It is also providing fully integrated customized services from R&D to Commercial scale manufacturing and packaging for its products to the Pharmaceutical, Agrochemical, Nutraceutical, Speciality Chemicals & various other chemical Industries. It supplies range of Iodine derivatives on Order to Made basis only.
Major Events
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
